12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Andexanet alfa: Additional Phase II data

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial in 27 healthy volunteers showed that 420 mg IV PRT4445 led to a >95% reversal of the anticoagulant activity of Eliquis apixaban within 2 minutes post-administration. Data were presented at the International Society on Thrombosis and Hemostasis meeting in Amsterdam. In May, Portola said preliminary data from the trial showed that PRT4445 produced "sustained, dose-related reversal" of anticoagulant activity of Eliquis (see BioCentury, May 13).

Last October, Portola partnered with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.) to evaluate...

Read the full 495 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >